Ashland's Q2 Earnings and Revenues Miss Estimates, Down Y/Y

06.05.25 14:49 Uhr

Werte in diesem Artikel
Aktien

71,00 EUR 1,50 EUR 2,16%

Ashland Global Holdings Inc. ASH recorded second-quarter fiscal 2025 (ended March 31, 2025) profit of $31 million or 65 cents, down from $120 million or $2.39 in the prior-year quarter.Barring one-time items, adjusted earnings came in at 99 cents, down from the year-ago quarter’s figure of $1.27. The bottom line missed the Zacks Consensus Estimate of $1.10.Sales were down 16.7% year over year to $479 million. The top line missed the Zacks Consensus Estimate of $508.8 million. Sales for the fiscal second quarter were adversely impacted by the portfolio optimization actions involving curtailing or divesting certain lower-margin products, lower volumes and prices.(Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)Ashland Inc. Price, Consensus and EPS Surprise Ashland Inc. price-consensus-eps-surprise-chart | Ashland Inc. QuoteASH’s Segment HighlightsLife Sciences: Sales in the segment were down 22.5% year over year to $172 million in the reported quarter. The Zacks Consensus Estimate for the same was $177 million. The decline was primarily caused by the divestiture of the Neutraceuticals division and the exit of the low-margin nutrition industry.Personal Care: Sales in the division declined 13.6% year over year to $146 million. The Zacks Consensus Estimate for the same was $162.3 million. The decrease was mostly due to portfolio optimization.Specialty Additives: Sales in the segment fell 14.6% year over year to $134 million. It missed the Zacks Consensus Estimate of $141.1 million. The decline was mostly due to portfolio optimization.Intermediates: Sales in the segment went down 7.5% year over year to $37 million. The figure modestly beat the consensus estimate of $36.3 million. The overall sales decreased, mostly due to lower prices.ASH’s FinancialsCash and cash equivalents were $168 million at the end of the quarter, down around 23% sequentially. Long-term debt was $1,336 million, up roughly 2% over the same time frame.ASH’s OutlookFor the full fiscal year, Ashland expects sales to be in the range of $1.825-$1.9 billion and adjusted EBITDA to be $400-$420 million.ASH’s Price PerformanceShares of Ashland have lost 49% in the past year against a 0.9% decline of the industry.Image Source: Zacks Investment ResearchASH’s Zacks Rank & Key PicksASH currently carries a Zacks Rank #4 (Sell).Better-ranked stocks worth a look in the basic materials space include Hawkins, Inc. HWKN, Franco-Nevada Corporation FNV and Coeur Mining CDE. While HWKN and CDE carry a Zacks Rank #1 (Strong Buy), SSRM has a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.Hawkins is scheduled to report fiscal fourth-quarter results on May 14. The consensus estimate for Hawkins’ earnings is pegged at 74 cents. HWKN beat the consensus estimate in one of the last four quarters while missing thrice, with the average earnings surprise being 6.1%. Franco-Nevada is slated to release first-quarter results on May 8. The consensus estimate for FNV’s first-quarter earnings is pegged at $1. The Zacks Consensus Estimate for first-quarter earnings has been going up over the past 60 days.Coeur Mining is slated to release first-quarter results on May 7. CDE delivered a trailing four-quarter earnings surprise of 27.9%, on average. Zacks' Research Chief Names "Stock Most Likely to Double"Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Ashland Inc. (ASH): Free Stock Analysis Report Franco-Nevada Corporation (FNV): Free Stock Analysis Report Coeur Mining, Inc. (CDE): Free Stock Analysis Report Hawkins, Inc. (HWKN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

In eigener Sache

Übrigens: Q2 und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Q2

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Q2

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Q2 Holdings Inc

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Wer­bung

Analysen zu Q2 Holdings Inc

DatumRatingAnalyst
13.08.2019Q2 BuyCompass Point
01.03.2019Q2 BuyNeedham & Company, LLC
19.12.2018Q2 BuyBTIG Research
09.08.2018Q2 BuyNeedham & Company, LLC
11.05.2018Q2 NeutralBTIG Research
DatumRatingAnalyst
13.08.2019Q2 BuyCompass Point
01.03.2019Q2 BuyNeedham & Company, LLC
19.12.2018Q2 BuyBTIG Research
09.08.2018Q2 BuyNeedham & Company, LLC
16.02.2018Q2 BuyNeedham & Company, LLC
DatumRatingAnalyst
11.05.2018Q2 NeutralBTIG Research
18.11.2016Q2 Sector WeightPacific Crest Securities Inc.
DatumRatingAnalyst

Keine Analysen im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten die älter als ein Jahr sind im Archiv

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Q2 Holdings Inc nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen